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Abstract
CHN is genetically heterogeneous and its genetic basis is difﬁcult to determine on features alone. CNTNAP1 encodes
CASPR, integral in the paranodal junction high molecular mass complex. Nineteen individuals with biallelic variants have
been described in association with severe congenital hypomyelinating neuropathy, respiratory compromise, profound
intellectual disability and death within the ﬁrst year. We report 7 additional patients ascertained through exome sequencing.
We identiﬁed 9 novel CNTNAP1 variants in 6 families: three missense variants, four nonsense variants, one frameshift
variant and one splice site variant. Signiﬁcant polyhydramnios occurred in 6/7 pregnancies. Severe respiratory compromise
was seen in 6/7 (tracheostomy in 5). A complex neurological phenotype was seen in all patients who had marked brain
hypomyelination/demyelination and profound developmental delay. Additional neurological ﬁndings included cranial nerve
compromise: orobulbar dysfunction in 5/7, facial nerve weakness in 4/7 and vocal cord paresis in 5/7. Dystonia occurred in
2/7 patients and limb contractures in 5/7. All had severe gastroesophageal reﬂux, and a gastrostomy was required in 5/7. In
contrast to most previous reports, only one patient died in the ﬁrst year of life. Protein modelling was performed for all
detected CNTNAP1 variants. We propose a genotype–phenotype correlation, whereby hypomorphic missense variants
partially ameliorate the phenotype, prolonging survival. This study suggests that biallelic variants in CNTNAP1 cause a
distinct recognisable syndrome, which is not caused by other genes associated with CHN. Neonates presenting with this
phenotype will beneﬁt from early genetic deﬁnition to inform clinical management and enable essential genetic counselling
for their families.
INTRODUCTION
Nerve ﬁbres are myelinated in segments to enable high
velocity conduction. This myelination occurs through the
wrapping of glial cells around the nerve ﬁbre in between
the nodes of Ranvier [1]. The nodes of Ranvier are
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ﬂanked by paranodal junctions and together they form
distinct domains, which are crucial for saltatory con-
duction. These junctions are composed of multiple
molecules, which include Drosophila Neurexin IV-
related protein, Caspr/Paranodin, initially termed ncp1
[1]. Ncp1, now more commonly referred to as the rat
contactin-associated protein, CASPR [2], forms part of a
high molecular mass complex in the paranodal junction
and interacts with contactin. In a homozygous null mouse
model (ncp1-/ncp1-), ataxia, tremor, hypomotility, wide-
based gait, signiﬁcant motor paresis and severely
decreased peripheral nerve conduction velocity was
associated with disorganization of the paranodal junc-
tions and dysregulation of ion channel interactions [1].
Death occurred within the ﬁrst month of life. Hetero-
zygous mice were unaffected at all ages. Immunohisto-
chemical studies demonstrated the expression of caspr at
the paranodal region in mouse sciatic nerve and the
central nervous system. These ﬁndings suggest that the
development of normal paranodal junctions is CASPR-
dependent and its absence leads to disruption of the
paranodal loops.
CNTNAP1 (MIM # 602346) encodes CASPR and was
ﬁrst implicated in human disease in 2014 [3]. Using the
whole-exome sequencing (WES) approach in 31 non-
syndromic fetal hypomobility/arthrogryposis multiplex
congenital families, Laquerriere et al. identiﬁed four
unrelated families with homozygous truncating variants
[3]. Death occurred within the ﬁrst 40 days of life in all
four cases. CNTNAP1 variants have since been described
in association with congenital hypomyelinating neuro-
pathy (CHN) [4], which comprises prenatal-onset
congenital neuropathy, areﬂexia, hypotonia, hypomyeli-
nation, slow nerve conduction velocities and arthro-
gryposis. Nizon et al. [5] described two brothers with
severe congenital hypotonia, foot deformities and mark-
edly decreased nerve conduction in association with
compound heterozygous variants in CNTNAP1, including
the ﬁrst causative missense variant. A separate study
investigated nerve biopsies of these brothers and an
additional sibling-pair with CHN who had compound
heterozygous nonsense/missense variants [6]. These
patients had identical hypomyelinated nerves with char-
acteristic lesions in the paranodal area where CASPR is
located, which were reminiscent of those in the sciatic
nerves of caspr-1 null mice. Mehta et al. [7] reported a
neonate with CHN who had homozygous CNTNAP1
missense variants that are predicted to affect function
with typical clinical presentation, absent sensory nerve
and compound muscle action potentials and hypomyeli-
nation on nerve biopsy, who died after withdrawal of life,
sustaining care at 1 month of age. In a WES study of 71
patients with white matter abnormalities, Vanderver et al.
[8] identiﬁed two further cases (one homozygous mis-
sense, one compound missense/nonsense), of CNTNAP1-
associated CHN. Very recently, two further reports [9,
10] have been published describing further 8 cases,
bringing the reported total to 19 (see Supplementary
Table 3 for review of previously reported cases).
Here we present clinical and molecular data from
seven additional patients with biallelic CNTNAP1 var-
iants identiﬁed via exome sequencing undertaken for
undiagnosed developmental disorders and CHN. The
clinical features we observed in these patients, and those
previously published, suggest that there is a distinct
CNTNAP1-related congenital hypomyelinating neuro-
pathy syndrome which is not always lethal in the neonatal
period.
METHODS
Patient ascertainment
Five of the affected patients were recruited via the
Deciphering Developmental Disorders (DDD) study
(www.ddduk.org) open to the UK NHS Regional
Genetics Services (see Table 1for associated Decipher
IDs) [11]. All ﬁve were the only affected cases in their
families. Patient 2 and 3 (siblings) were recruited through
their local Clinical Geneticist. All patients were assessed
by their Clinical Geneticist who assisted with systematic
detailed phenotyping. Patient growth centiles and z scores
were calculated using UK WHO data (www.rcpch.ac.uk/
growthcharts).
Exome library preparation and sequencing
Trio-based exome sequencing was undertaken for the ﬁve
affected patients and their parents via the DDD study using
the approach which has been described elsewhere [12]. A
sibling pair analysis was carried out in patients 2 and 3.
Their DNA samples were fragmented using the Bioruptor
(Diagenode, Liège, Belgium), and indexed adaptors ligated
before hybridization with the Agilent SureSelect All Exon
v5 capture kit (Santa Clara, CA, USA). Paired-end 100-bp
reads were sequenced on a HiSeq 2500 (Illumina, San
Diego, CA, USA) to generate 75 million reads with >100×
mean coverage and >95% of target bases at ≥20×. The
Illumina HiSeq FASTQ sequencing reads were de-
multiplexed and aligned to the reference (GRCh37/Hg19)
using BWA-MEM, this is converted to BAM format ﬁle
and duplicates removed using Picard. GATK (v3.4) was
used for indel realignment, variant calling and quality
ﬁltering.
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Variant ﬁltering and interpretation
Variants were annotated using Alamut-batch and a
bioinformatics pipeline was designed in-house to identify
shared genes where both siblings had a compound het-
erozygous, homozygous or X-linked recessive variant
predicted to affect function. The following criteria were
applied to detect rare potentially deleterious variants:
minor allele frequency (MAF) > 1% in dbSNP137 var-
iants to exclude known variants and include those with a
MAF < 0.0001 (<0.01%) and 0.001 (<0.1%) in Exome
aggregation consortium (ExAC http://exac.broadinstitute.
org/), Exome variant server (EVS http://evs.gs.wa
shington.edu/EVS/) or 1000 Genomes (http://www.
internationalgenome.org/). Variants were restricted to
non-synonymous, those affecting the conserved splice
sites or those within−50/+ 10 base pairs of ﬂanking
exons predicted by Alamut-batch to affect splicing.
Biparental inheritance of the CNTNAP1 variants was
conﬁrmed by PCR/Sanger Sequencing (PCR primers
available on request). Exonic variants are described
according to NM_003632.2 and intronic variants
according to NG_042091.1. CNTNAP1 variants identiﬁed
in this study were classiﬁed according to the American
College of Medical Genetics and Genomics (ACMG)
guidelines (See Supplementary Table 1 and Table 1) [13].
The data are deposited in DECIPHER and can be viewed
per DECIPHER IDs provided (Patient 3 has not been
deposited but the data are the same as for patient 2, his
brother).
Protein modelling
A composite, multi-template structure for CASPR was
generated using the Phyre2 server (http://www.sbg.bio.ic.
ac.uk/phyre2/html/page.cgi?id= index) [14] in intensive
modelling mode; individual variants were then re-
modeled on appropriate templates using the Swiss-
Model server (http://swissmodel.expasy.org/) [15] in
automated mode. All coordinate ﬁles were downloaded
and visualized in PyMOL version 1.8.4.0 (Schrödinger,
LLC).
RESULTS
The clinical features and CNTNAP1 variants in the 3
female and 4 male patients, from 6 different families,
compared with the previously reported cases [3, 5–10] are
presented in Table 1. All 7 patients had profound intel-
lectual disability (ID) and a strikingly severe neurological
phenotype. None of the patients had any other observed
genomic aberrations.
Perinatal
Signiﬁcant polyhydramnios occurred in all but one preg-
nancy. This was associated with preterm labour in 5 but no
patients were born at <30 weeks’ gestation. In the single
pregnancy with normal liquor volume the baby was born at
term. In all patients the birthweights and head circumfer-
ences were within the normal range, but 6 out of made
minimal respiratory effort, were extremely hypotonic and
required rapid resuscitation. Patient 7 was the most pro-
foundly affected and following extensive investigations,
died at the age of 3 months.
Neurology, neuropathology and development
All cases had both central and peripheral hypotonia, with
variably demyelinating/hypomyelinating neuropathy and
variable additional neurological signs: patient 1 had nys-
tagmus, ataxia, tremor, head titubation and 2 other cases had
dystonia. MRI brains scans consistently showed hypomye-
lination/demyelination, variably reduced white matter bulk
and cerebral atrophy. The results of the nerve biopsies for
patients 1,2,3,4 are shown in Fig. 1. The muscle biopsies
were non-speciﬁc and did not show any neurogenic
pathology despite the ﬁndings of hypomyelination in the
nerve biopsies. This might reﬂect the time course, as many
of the muscle biopsies were taken early on during the dis-
ease, and in most cases, a substantial time prior to the nerve
biopsies. All our patients had severely delayed development
except one. He had a social smile at the age of 12 weeks and
is attempting single words at the age of 2. Patient 1, the
oldest in the cohort, can communicate some preferences
through noise and body language and is described as
enjoying certain television programmes.
Respiratory
Six out of 7 patients had severe respiratory distress at birth,
5 requiring tracheostomy. In the sixth case, a tracheostomy
was not considered appropriate as the prognosis was poor.
In patients 2 and 3, the tracheostomies were successfully
decannulated, with both boys requiring overnight non-
invasive ventilation. However, both boys have subsequently
required re-insertion of their tracheostomies due to issues
with repeated respiratory infections and respiratory com-
promise, which have resulted in multiple intensive care/high
dependency unit admissions.
Dysmorphology
The facial features of the patients are depicted in Fig. 2. All
patients have consistent myopathic facial features (Fig. 2)
and one a naevus ﬂammus.
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Other features
Gum hyperplasia is seen in 2 patients, one of whom had
extra teeth. All patients had a typical ‘cathedral’ palate, but
only patient 7 had a cleft. An anterior larynx with lar-
yngomalacia was reported in patient 5. Patient 6 has a
resting tachycardia of unknown cause. Patient 4 has small
nails, and severe eczema with overlying abnormal skin
pigmentation.
Variants
We identiﬁed 9 novel CNTNAP1 variants that are predicted
to affect CNTNAP1 function in 6 families by whole-exome
sequencing (Table 1). These included three missense var-
iants, four nonsense variants, one frameshift variant and one
splice site variant. Two patients from consanguineous
families were homozygous for a novel missense (c.2141 G
> C, p.(Arg714Pro)—patient 1)) and a nonsense variant
Fig. 1 a Normal nerve, transverse section, H&E 40 × ; (b) Normal
nerve, transverse section, Sol. Cyan 40 × ; (c) Normal nerve,
longitudinal section, H&E 40 × ; (d) normal nerve, longitudinal
section, Sol. Cyan 40 × . All normal nerve sections highlight a
normal population of myelinated nerve ﬁbres of appropriate thick-
ness; (e, f) patient 1: Sural Nerve biopsy (TS) at 9 years of age
showing marked loss of large diameter (thickly myelinated) nerve
ﬁbres, thinly myelinated ﬁbres for axon size, and clusters of thinly
myelinated ﬁbres (axonal sprouting) on H&E (e) and Sol. Cyan (f)
in keeping with hypomyelinating neuropathy; (g, h) patient 2: Sural
Nerve biopsy (TS) at 10 months of age showing modest loss of
large diameter (thickly myelinated) ﬁbres, presence of thinly mye-
linated ﬁbres, clusters of thinly myelinated ﬁbres and a rare onion
bulb on H&E (g) and Sol.Cyan (h) consistent with hypomyelina-
tion; (i, j) Patient 7: Sural Nerve biopsy (LS) following death at
3 months of age (autopsy specimen). Demonstrates widespread,
almost complete loss of myelinated ﬁbres on H&E (i) and Sol. Cyan
(j) with a few residual thinly myelinated ﬁbres. k Patient 2: Electron
microscopy (EM) highlighting clusters of thinly myelinated ﬁbres
with only a few residual appropriately myelinated ﬁbres. Inset
highlights single onion bulb in keeping with active demyelination.
l. Patient 7: EM highlighting extensive loss of myelinated nerve
ﬁbres with a residual rare thinly myelinated ﬁbre. m Electron
Microscopy of a normal nerve showing a normal complement of
large myelinated ﬁbres and thinly myelinated ﬁbres with propor-
tionate axons
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(c.2344 C > T, p.(Arg782Ter)–patient 4. In each family, the
parents were heterozygous carriers of the compound het-
erozygous or homozygous variants identiﬁed in the affected
proband. The other 5 patients were compound hetero-
zygotes for either two protein truncating variants (patients 5
and 7) or a missense and nonsense variant (patients 2 and 3,
Fig. 3) or a frameshift and missense variant (patient 6). One
of the nonsense variants, c.2344 C > T p.(Arg782Ter), was
identiﬁed in two families. All variants described in this
study and those previously reported to affect function are
shown in Fig. 4. The three novel missense variants were
predicted to be affecting function according to the ACMG
guidelines (Table 1, and Supplementary Table 1).
Protein modelling
Since there are no experimental structures for any regions of
CASPR, a 3-dimensional structure of the protein was pre-
dicted using the Phyre2 protein modelling server (Fig. 5). A
high conﬁdence model was obtained for a contiguous region
covering residues 21–960 of CASPR, which includes all
novel missense variants reported here or previously identi-
ﬁed as affecting function (Fig. 5a). All substitutions lie
within conserved structural and functional domains and thus
could potentially cause deleterious effects on CASPR
function. To examine the effects of speciﬁc variants, tem-
plate structures used by Phyre2 for calculation of the
composite model were used to re-model wild-type and
variant sequences over the appropriate regions. Modelling
suggested that all missense variants were likely to affect the
underlying structure of CASPR, to a greater or lesser extent,
which is consistent with loss of protein function. For
example, the p.(Leu212Pro) and p.(Cys323Arg) variants
both lie in the ﬁrst Laminin G-like domain of CASPR
(residues 203–355). Predictive modelling showed that p.
Cys323 forms a disulphide bond to p.Cys355, stabilizing
the loop region between this domain and the following
Laminin G-like domain 2 (Fig. 5b). This bond is disrupted
by the p.(Cys323Arg) variant, likely leading to
destabilization and impaired folding of the protein in this
region (Fig. 5c). Similarly, the p.(Leu212Pro) substitution
was predicted to interrupt a region of β-strand (Fig. 5d),
which is also likely to result in impaired folding of this
domain. The p.(Arg764Cys) variant, which lies in the core
of the Fibrinogen C-terminal domain of CASPR, was also
predicted to have a strong effect on the underlying domain
structure, while variants p.(Pro50Gln), p.(Arg388Pro) and
p.(Arg714Pro) either occur in ﬂexible loop regions or were
expected to have lesser impact on the domain structure (data
not shown). The predicted effects of all variants are sum-
marized in Supplementary Table 2.
Discussion
This series of patients extends the phenotype of CNTNAP1-
related CHN and indicates that survival into infancy and
childhood can occur in this condition. By contrast, of the 19
(the number of individuals refers to the number of individuals
who have been speciﬁcally reported in the literature. Several
case reports refer to further siblings or family members with
either very limited data and/or no testing and we have not
included them in this total count) previously published cases,
only 6 survived infancy. Vanderver et al. reported 2 patients
who were 6 years old, although both had a sibling who died
of respiratory compromise. Hengel et al. very recently
reported a family with 3 children with a homozygous trun-
cating variant, all of whom are alive. Lakhani et al. likewise
reported a family in which one child remains alive at age 13
“in a persistent vegetative state” although two affected sib-
lings died within the ﬁrst hour of life. Amongst our cohort,
only one child followed similar early demise compared to the
majority of those reported. Furthermore, one of our patients
had no neonatal respiratory distress and experienced few
respiratory problems by her current age of 15 years,
demonstrating the potenially broad phenotypic spectrum
associated with CNTNAP1 variants. This discrepancy may
reﬂect differences in the ascertainment of the children—the
Fig. 2 Facial features of patients 1,2,3,4,6,7 from left to right. Patient 1
is reported with the mildest phenotype, which is apparent from the
photo comparisons and makes her appear more atypical. Note the
consistent narrow down-slanting palpebral ﬁssures, full rounded eye-
brows, myopathic facies and mouth held wide open. Tracheostomy is
shown in patients 2,3, 4 and 6
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majority of the cases in our study were diagnosed through a
WES looking for diagnoses in children with developmental
delay, which focussed (albeit not exclusively) on living
children. This proves that the spectrum of disease is broader
than previously thought.
While all previously described patients and most of ours
had marked ID, we recognised that two of our patients had
made some progress, so developmental delay in CNTNAP1-
related CHM may not always be profound. One of our
patients had a cleft palate and Vanderver et al [8] reported a
Fig. 3 Sanger sequencing of
variants identiﬁed in CNTNAP1
in the affected brothers (patients
2 and 3) and their parents.
Open symbols: unaffected; ﬁlled
symbols: affected; square
symbols: male and circular
symbols: female The nucleotide
and amino acid changes are
indicated
Fig. 4 Representation of the
CASPR protein showing
functional domains and
approximate location of all
reported variants to date. Those
marked with an * were identiﬁed
in this study, others are marked
with the paper reference.
Variants are described according
to NM_003632.2, NG_042091.1
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single patient with a submucosal cleft palate. Hengel et al.
have now also reported this feature in two of their patients
and so this may represent a less frequent phenotypic asso-
ciation with CNTNAP1-CHN (4/26). We also noted thick-
ened gums in two of our patients and this has also been
reported in one patient by Hengel et al., again possibly
representing a less frequently reported association, although
it is possible this was also not speciﬁcally looked for or
noted in previous reports.
Early-onset hereditary neuropathies can be described in
terms of age of onset and hence divided in to CHN and
Dejerine–Sottas neuropathy starting in infancy [16]. De
novo dominant variants predicted to affect function have
been well reported in association with early-onset neuro-
pathies in PMP22, MPZ [16–19] and EGR2 [20, 21,]. In
addition, variants in other Hereditary Motor and Sensory
Neuropathy genes have been associated with overlapping
phenotypes. Baets et al. [16] performed direct sequencing of
the coding regions of MFN2, PMP22, MPZ, EGR2,
GDAP1, NEFL, FGD4, MTMR2, PRX, SBF2 and SH3TC2
in 77 isolated cases of hereditary neuropathy starting in the
ﬁrst year of life. They detected variants predicted to affect
function in 35 patients but only three are described as
having respiratory insufﬁciency. One, who ﬁrst came to
medical attention due to delayed motor milestones, had a
variant in SH3TC2, but had less marked hypotonia and was
able to walk at 24 months. Another with congenital hypo-
tonia and respiratory problems in the neonatal period, had a
variant in MPZ However the clinical picture appeared
milder than in our cohort: the patient was able to walk with
support until the age of 6 years, after which he was
wheelchair bound. MPZ has been reported in association
with a CHN picture, but usually without the respiratory
problems by us. [16–19] Furthermore, while the symptoms
are of early onset, the weakness is not as severe and walking
has been achieved by patients. Unlike in CNTNAP1-CHN,
Fig. 5 Comparative modelling of CASPR. a Predicted structure of
CASPR residues 21–960. The sequence of CASPR (residues 1–1384)
was modeled using the Phyre2 server; a multi-template, high-
conﬁdence model (~98% of residues modeled at > 90% conﬁdence)
was obtained for a contiguous region spanning residues 21–960, which
includes most of the extracellular domain (1–1284) and includes all
missense variants discussed here. The protein is shown in ribbon
format coloured by secondary structure succession (N-terminal, blue to
C-terminal, red); the sidechains of positions of missense variants are
shown in stick format and labelled; domain annotation is taken from
the InterPro database entry for CASPR (http://www.ebi.ac.uk/interpro/
protein/P78357). b–d Modelling of the Laminin G-like 1 domain only
(residues 174–355), based on template 3poyA, for wild-type CASPR
and variants p.Cys323Arg and p.Leu212Pro respectively; protein is
shown in ribbon format, coloured by secondary structure type (red, α-
helix; yellow, β-strand; green, loop); the disulphide bond between
cysteines 323 and 355 in B is shown by a yellow line; view is rotated
compared to Fig. 4a for clarity
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cranial nerve involvement is not reported in association with
variants in MPZ. The third patient had a variant in EGR2
but was able to walk at the age of 3, and is therefore distinct
from patients in our cohort. Variants in EGR2 [20, 21,] have
previously been reported in association with severe CHN
and compromise of cranial nerve function. None of the
patients with variants in these 3 genes have had the severe
respiratory insufﬁciency from birth as we describe. Addi-
tionally, patients with variants in EGR2 can have normal
intellect-a clear difference from the phenotype of
CNTNAP1-CHN. Polyhydramnios and associated pre-
mature labour, does not appear to be a feature in any of
these other groups and therefore provides a clue in the
severe neonatal presentation of CHN with respiratory
insufﬁciency. Hearing and visual impairment are not a
widely reported ﬁnding in CHN in association with any of
these other genes and again this appears to be a speciﬁc
ﬁnding in CNTNAP1-CHN although it is not seen in all
patients.
Comparative modelling of the missense variants suggests
a possible genotype–phenotype relationship, in that those
substitutions which are expected to have the least effect on
protein structure seem to correlate with a milder phenotype
in our patients. Patient 1, who has a CNTNAP1 homozygous
missense variant (c.2141[G > C];[G > C], p.[(Arg714Pro)];
[(Arg714Pro)], has no respiratory problems, which is
striking compared to the rest of the group. Protein model-
ling has shown that while the variant may disrupt ligand
interactions, the underlying secondary structure of the pro-
tein and structural core remain unchanged. This could
account for the respiratory and other phenotypic differences.
Patient 6 appears to be making the most progress devel-
opmentally (c.[149 C > A];[c.2600del], p.[(Pro50Gln)];
[(Asp867fs)]). The p.(Pro50Gln) variant is modelled to
cause a possible altered topology of local loop with low
impact. This hypomorphic variant may be partially ameli-
orating the phenotype in this child. In comparison, our only
patient who died at few months of age, had compound
heterozygous nonsense variants. We therefore speculate that
there may be a genotype–phenotype relationship in which
hypomorphic missense variants modify the deleterious
effect on peripheral/central myelination and development of
paranodal junctions. However, we acknowledge that, at
present, there are only a very limited number of known
affecting function missense variants in CNTNAP1 and the
role of various domains in CASPR in ligand binding is still
poorly understood. Investigation of further patients with
CNTNAP1-CHN and functional assays to assess the effects
on protein structure/function will elucidate this relationship.
There does not appear to be a clear molecular mechanism to
account for the CHN presentation vs. the AMC presenta-
tion. It is noteworthy as well that Hengel et al. reported a
family of three affected siblings, in whom two siblings had
AMC and the third did not. It is possible that these differ-
ences are more to do with diagnostic labelling and that this
all represents a spectrum of CNTNAP1 related disease.
Conclusion
Our study, in combination with previous reports,
demonstrates that biallelic variants in CNTNAP1 cause a
distinct recognisable syndrome of polyhydramnios, severe
congenital hypomyelinating neuropathy with central hypo-
tonia and cranial nerve involvement, severe respiratory
insufﬁciency often necessitating tracheostomy, profound
developmental delay/intellectual disability. Hearing and
visual impairment may be a signiﬁcant further clue to this
diagnosis. In contrast with previous reports, a signiﬁcant
number of patients with CNTNAP1-CHN may survive
infancy into childhood. Hypomorphic missense variants
may inﬂuence the severity of the phenotype, resulting in a
less severe picture. Further cases will conﬁrm the full
clinical spectrum of this disorder and genetic/functional
studies will clarify and extend the implicatons of our protein
modelling. Neonates presenting with this phenotype will
beneﬁt from early genetic deﬁnition to inform clinical
management and enable essential genetic counselling for
their families.
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